| Common Brands | Cablivi |
|---|---|
|
Drug Class |
Monoclonal Antibody |
|
Controlled Substance Classification |
Not a controlled medication |
|
Generic Status |
Lower-cost generic available |
|
Availability |
Prescription only |
Caplacizumab is a monoclonal antibody intended for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). The disease is characterized by small blood clots formed all over the body as a result of abnormal platelet aggregation, which results in damage to organs, thrombocytopenia, and potentially life-threatening complications.
Caplacizumab is used in conjunction with plasma exchange and immunosuppressive therapy to treat and to prevent the reoccurrence of aTTP in adults. It specifically targets and binds to von Willebrand factor (vWF) and prevents the interaction between vWF and platelets, thus inhibiting abnormal clotting in aTTP.
Caplacizumab is generally administered by a subcutaneous injection. For the treatment of adults diagnosed with aTTP, this is prescribed as follows:
Loading Dose: 10 mg once daily for the first 4 days, starting on the day of plasma exchange and continuing until the platelet count reaches a sufficient level.
Maintenance Dose: After the loading dose, 10 mg once a day is typically administered for up to 30 days, depending on the patient’s platelet count and clinical condition.
Subsequent Dosing: After managing the acute episode and achieving a stable platelet count, Caplacizumab can be withdrawn or reduced in dose according to the healthcare provider’s discretion.
Caplacizumab must be administered concurrently with plasma exchange therapy as well as all other therapies prescribed by the healthcare provider for aTTP treatment.
Caplacizumab works by binding to the A1 domain of the von Willebrand factor (vWF). This binding blocks the ability of vWF to interact with platelet glycoprotein Ib (GP-Ib), which is a crucial step in platelet aggregation and clot formation.
Platelet aggregation inhibition: By preventing vWF from binding to platelets, Caplacizumab stops the formation of abnormal clots that are characteristic of aTTP.
Prevention of thrombotic events: This helps reduce the risks of thrombotic microangiopathy, damage to organs, and the occurrence of complications such as stroke, renal failure, and hemolysis or the destruction of red blood cells.
Though Caplacizumab is generally well-tolerated, it may cause side effects in some patients. Common and serious side effects include:
Headache: Some patients experience mild to moderate headaches during treatment.
Fatigue: Tiredness or fatigue could be another side effect.
Nausea: There may be mild nausea in some patients.
Bleeding: As Caplacizumab prevents the formation of clots, it will increase the chances of getting bleeding. These include easy bruising, protracted bleeding, nosebleeds, or bleeding gums.
Thrombocytopenia: Although Caplacizumab is used for the management of platelet count, sometimes it may be a causative agent for low platelet counts.
Hypersensitivity Reactions: Some patients may exhibit an allergic response to Caplacizumab, like rash, itchiness, or difficulty in breathing.
Risk of Bleeding: Caplacizumab will potentially cause increased risk of bleeding, as the mechanism of its action interferes with the ability of platelets to aggregate;
Pregnancy and Breast-feeding: Caplacizumab should be used cautiously in pregnant or breastfeeding women. The effects of Caplacizumab on fetal development or nursing infants are not well known..
Monitoring: During treatment with Caplacizumab, healthcare providers will closely monitor platelet counts, coagulation status, and other parameters to ensure safety and efficacy.
Discontinuation: If a patient exhibits severe bleeding, the Caplacizumab might need to be discontinued. That will depend on the clinical circumstances, including the severity of bleeding and the overall clinical picture.
Caplacizumab, an anti-von Willebrand factor (vWF) monoclonal antibody used to treat acquired thrombotic thrombocytopenic purpura (aTTP), interacts with various medications, affecting bleeding risk and efficacy.
The proper dose of Caplacizumab, as it is one of the biologic treatments, should be determined by the healthcare provider based on individualized considerations of the patient’s clinical status. The guidelines follow:
Initiation of Therapy: Caplacizumab is initiated in a hospital or on a medical facility visit when the patient undergoes plasma exchange therapy. The initiating dose is 10 mg, administered once daily for the first 4 days followed by maintenance doses.
Platelet Count Monitoring: Platelet counts will be monitored regularly during the treatment to ascertain if the drug is working appropriately and to avoid complications like severe bleeding.
Caplacizumab is only available through prescription and only by a health care provider. It usually comes from hematologists or oncologists with specializations in blood disorders. There is no over-the-counter formulation of this drug, and medical supervision is recommended for administering it due to the possible risks and the need to monitor patients taking it.
Caplacizumab is a therapeutic monoclonal antibody used primarily to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP).
Caplacizumab works by inhibiting the interaction between von Willebrand factor and platelets, thus preventing the formation of blood clots in the microvasculature.
Caplacizumab is primarily approved for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
aTTP is a rare blood disorder characterized by the formation of small clots in the blood vessels, leading to low platelet counts, hemolytic anemia, and organ damage.
Caplacizumab is administered via subcutaneous injection, typically starting with an injection before plasma exchange therapy.
Common side effects may include bleeding, headache, and injection site reactions. It’s important to monitor for signs of serious bleeding.
As of now, Caplacizumab has not been approved for use in pediatric patients; its safety and efficacy in children have not been established.
Caplacizumab should not be used in patients with a known allergy to the drug or any of its components, or in those with active bleeding disorders not caused by aTTP.
The treatment with Caplacizumab is typically continued for at least 30 days or until the resolution of the underlying condition.
If you miss a dose, you should take it as soon as you remember, but if it’s close to the time of the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.
While Caplacizumab itself doesn’t directly cause infections, the bleeding risk may complicate existing infections. Consult your healthcare provider for personalized advice.
Caplacizumab can potentially interact with other anticoagulants or antiplatelet agents, increasing the risk of bleeding. Always inform your healthcare provider about all medications you are taking.
Patients on Caplacizumab should be regularly monitored for platelet counts, signs of bleeding, and overall response to treatment.
Caplacizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Its safety during breastfeeding is not established; consult your doctor for advice.
Serious side effects can include severe allergic reactions (anaphylaxis), major bleeding, and intracranial hemorrhage.
Caplacizumab is not intended for long-term management of aTTP; it is primarily used to treat episodes and requires ongoing monitoring after treatment cessation.
Caplacizumab blocks the interaction of von Willebrand factor with platelets, which aids in diminishing the inappropriate clotting that characterizes aTTP.
Caplacizumab should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) and should not be frozen.
There are no specific dietary restrictions associated with Caplacizumab; however, maintaining a healthy diet is always recommended for overall wellness.
Caplacizumab can be obtained through specialty pharmacies or hospitals, and patients should consult their healthcare provider to initiate therapy.
Seborrheic dermatitis is a widespread chronic inflammatory skin disorder that primarily affects the head, scalp, and upper trunk, which are areas rich in sebaceous glands.
For a considerable time, both scientists and medical experts have been fascinated by the connection between the gastrointestinal tract and the brain. The gut-brain axis
Food intolerances are becoming more widely acknowledged as serious health issues impacting people all over the world. In contrast to food allergies, which are immune
